Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2024-04-11 Capital/Financing Update
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a Securities Purchase Agreement involving a private placement of common stock and pre-funded warrants, detailing the terms of the transaction, use of proceeds, and registration rights. It also references exhibits including the agreement and warrants, a press release, and a corporate presentation. The document is not a full financial report, earnings release, or management discussion, but rather an update on a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 11,000 characters, indicating it is a full report, not just an announcement of a report.
2024-04-11 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement of a report. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or other specific report type.
2024-03-25 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC by Leap Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 used for registering securities for sale to the public. The text includes detailed information about the company, the securities being registered, risk factors, use of proceeds, and other legal and financial disclosures typical of a registration statement. It is not an annual report, earnings release, or any other report type but specifically a capital markets filing related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement of a filing, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2024-03-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 18, 2024, reporting the announcement of financial results for the fourth quarter and year ended December 31, 2023. It includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The text explicitly states that the information is furnished as an exhibit and is not incorporated by reference into other filings. The document length is 4391 characters, which is relatively short and consistent with a current report rather than a full financial report. According to the rules, a Form 8-K announcing financial results but primarily containing a press release and not the full report is classified as a Regulatory Filing (RNS) rather than an Annual Report (10-K) or Interim Report (IR).
2024-03-18 English
10-K
Annual Report FY 2023
2024-03-18 English
SC 13G/A
Major Shareholding Notification
2024-02-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.